The involvement of epithelial Fas in a XXXX model of graft versus host disease.

@entity1 @entity1197 @entity12 @entity2132
BACKGROUND: @entity2132 ( @entity2132 ) is an important complication occurring after hematopoietic stem-cell transplantation (HSCT). Animal model studies have shown the involvement of the Fas ( @entity1197 / @entity1197 )/Fas-Ligand pathway in @entity2132 pathogenesis, but its association with cutaneous @entity2132 in @entity1 remains to be established. METHODS: In the present study, Fas involvement in skin damage was assessed using a @entity1 skin explant model of @entity2132 . Fas and @entity12 expression were measured by immunohistochemistry and blockade of Fas pathway was investigated using an antagonistic anti-human Fas monoclonal antibody. In addition, levels of soluble Fas (sFas) were determined in the serum of @entity1 receiving allogeneic HSCT with and without @entity2132 . RESULTS: The results showed that Fas up-regulation in the epithelium of @entity1 skin explants correlated with @entity2132 ( @entity2132 ) in the skin explant model (P<0.001). Decreased @entity2132 grades were observed by using a Fas blocking monoclonal antibody. Levels of sFas were increased post-HSCT (P<0.001) but rather than being associated with the severity of @entity2132 , sFas levels differed with the conditioning treatments the @entity1 received before the HSCT. CONCLUSIONS: Higher @entity2132 grades were associated with increased Fas expression in the epithelium of the skin explants. In addition, by blocking Fas-mediated apoptosis, the @entity2132 grades were decreased. Our study thus shows the involvement of Fas in cutaneous @entity2132 , and supports the potential use of Fas as a therapeutic target.
